Our company news

We are working on the following new projects: • We signed the contract for the development of a scientific article based on the results of the observation program in chronic hepatitis C genotypes 1 to 6 in the Russian Federation.

We are constantly working to improve our IT solutions and now we have set up the eCRF of version 2.0 with advanced data validation capability. New modules

We are working on the following new projects: We signed a new contract for BE trial with our Indian long-term sponsor.

We are working on the following new projects: Our company was awarded with medical writing of an article based on the study report from Chronic Hepatitis C in Russian Federation.

We are working on the following new projects: We are preparing a contract for a phase 1 clinical trial with Dalteparin sodium. Our company signed a contract signature for the observational program with a top ten pharma.

We are working on the following new projects: Smooth is signing a contract for a bioequivalence trial of the Ibuprofen with our long-term client in Russia. Our company started activities for regulatory support for a global CRO.

We are working on the following new projects: • Smooth won a bidding for the international phase III clinical trial of the original drug for the patients with chronic myeloid leukemia. The study will take place in India, Belarus, and Russia.

We are working on the following new projects: • We signed 2 contracts with a new sponsor for bioequivalence studies of the drugs with INN Rivaroxaban (dosages 10 and 20 mg)

Clinical Trials Day is celebrated around the world 0n 20 of May.

We are working on the following new projects: • Smooth was awarded by 4 projects in Russia for medical writing and data management and 1 in Lithuania for data management.

We are working on the following new projects: • We signed a WO for CTD modules preparation with our global Sponsor. • We signed 2 contracts for specification documents

We are happy to present our new signed projects: • Contract for CTA submission of the final report with a new Sponsor. • Agreement for a bioequivalence study (INN: Dutasteride + Tamsulosin).

New contracts were signed in December: • A contract for submission of the final report to the Ministry of Health of the Russian Federation. • Medical writing agreement with our long-term Sponsor.

New projects started in November: • Bioequivalence trial (INN: Azacitidine). • Medical writing project (INN: Amtolmetin guacil).

We were working on the following new projects in October: • We signed a contract for data management and medical writing project of clinical study in Russia.